-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alcon and Aerie Pharmaceuticals announced that they have reached an agreement that Alcon will spend about $770 million to acquire Aerie
Aerie's research therapy AR-15512 is a small molecule TRPM8 ion channel agonist that represents an innovative mechanism
In a Phase 2 clinical trial, AR-15512 significantly increased the level of tear secretion in patients after 1 or 14 days of use, while the patients' symptoms were significantly relieved
▲Aerie product pipeline (Image source: Aerie official website)
"Alcon is committed to developing innovative ophthalmic therapies, especially in the areas of
Original english:
Original english: